ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
CSL LIMITED
175.540
+1.900
1.09%
成交量：
6.86萬
成交額：
1,199.80萬
市值：
840.68億
市盈率：
-23.51
高：
175.970
開：
173.955
低：
173.950
收：
173.640
52周最高：
219.589
52周最低：
90.000
股本：
4.79億
流通股本：
4.79億
量比：
2.49
換手率：
0.01%
股息：
4.08
股息率：
2.32%
每股收益(TTM):
-7.467
每股收益(LYR):
-7.467
淨資產收益率：
-15.83%
總資產收益率：
7.26%
市淨率：
4.07
市盈率(LYR):
-23.51
資料載入中...
總覽
公司
新聞資訊
公告
澳大利亞TGA：特定苄星青黴素鈉注射液產品將持續供應至庫存耗盡
美股速递
·
05/27
CSL加拿大宣佈首例加拿大患者於安大略省接受Hemgenix®血友病B基因療法
美股速递
·
05/20
泛美衞生組織簽署協議 為拉美及加勒比地區預留大流行流感疫苗供應
美股速递
·
05/13
異動解讀 | 花旗下調評級與目標價，CSL盤中大跌5.74%
异动解读
·
05/12
熱門話題-花旗下調目標價，晨星敦促公司聘請新首席執行官，CSL股價下跌6%
路透中文
·
05/12
異動解讀 | CSL預計美國免疫球蛋白渠道庫存正常化影響收入，股價盤中大跌10.49%
异动解读
·
05/11
CSL有限公司下調財年展望並計提50億澳元減值，早盤股價重挫10.8%
美股速递
·
05/11
CSL預計美國免疫球蛋白渠道庫存正常化將影響2026財年3億美元收入
美股速递
·
05/11
澳大利亞 CSL 受五角大樓流感政策轉變影響，股價跌至 2017 年新低
路透中文
·
04/23
BUZZ-花旗銀行認為季度增長強勁，但可能對瑞思邁的成本產生影響
路透中文
·
04/09
美國行政公告確認血漿衍生療法的獨特性，CSL有限公司受益
美股速递
·
04/07
CSL 表示出血性疾病基因療法全球缺貨
路透中文
·
03/18
CSL有限公司正與監管機構協作制定策略 確保Hemgenix持續穩定供應
美股速递
·
03/17
CSL Seqirus將攜手長期合作伙伴Sinergium Biotech 供應差異化流感疫苗組合
美股速递
·
03/10
世衞組織若宣佈流感大流行 CSL旗下Seqirus將為加拿大提供佐劑化細胞培養疫苗
美股速递
·
03/05
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/CSL.AU/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":175.54,"timestamp":1787702586931,"preClose":173.64,"halted":0,"volume":68644,"delay":0,"changeRate":0.010942179221377597,"nameEN":"CSL LIMITED","floatShares":478911979,"shares":478911979,"eps":-7.466852756454989,"marketStatus":"交易中","change":1.9,"latestTime":"08-26 10:03:07 AEST","open":173.955,"high":175.97,"low":173.95,"amount":11998016,"amplitude":0.011633,"askPrice":175.57,"askSize":15,"bidPrice":175.5,"bidSize":33,"shortable":3,"etf":0,"ttmEps":-7.466852756454989,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787724000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":173.64,"dividendRate":0.02325,"openAndCloseTimeList":[[1787702400000,1787724000000]],"volumeRatio":2.494992,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CSL.AU","preClose":173.64,"auctionPrice":174,"auctionVolume":20897,"auctionTime":1787702352433,"referenceTime":1787653803093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787702352433}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":478911979,"roa":"7.26%","roe":"-15.83%","lyrEps":-7.466853,"volumeRatio":2.494992,"shares":478911979,"dividePrice":4.075366,"high":175.97,"amplitude":0.011633,"preClose":173.64,"low":173.95,"week52Low":90,"pbRate":"4.07","psRate":"3.81","week52High":219.589,"institutionHeld":0,"latestPrice":175.54,"committee":0.375,"eps":-7.466852756454989,"divideRate":0.023216,"volume":68644,"delay":0,"ttmEps":-7.466852756454989,"open":173.955,"prevYearClose":170.408,"prevWeekClose":168.3,"prevMonthClose":123.06,"prevQuarterClose":114.74,"fiveDayClose":166.48,"twentyDayClose":128.07,"sixtyDayClose":92.56,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":5,"dividendGrowthRate":0.003543182641490467,"fiveYearAvgDividendRate":0.018567360626050477},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2026-08-18","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-09-10","defaultRemindTime":1788912000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-02","payableDate":"2026-09-10","currency":"USD","dateTimestamp":1788876000000,"payDate":"2026-10-02"},{"date":"2026-08-18","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787011200000,"name":null,"time":"","dateTimestamp":1786975200000,"actualEps":null},{"date":"2026-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2026-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2026-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-09","payableDate":"2026-03-11","currency":"USD","dateTimestamp":1773061200000,"payDate":"2026-04-09"},{"date":"2026-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770764400000,"name":null,"time":"","dateTimestamp":1770728400000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1129937392","title":"澳大利亞TGA：特定苄星青黴素鈉注射液產品將持續供應至庫存耗盡","url":"https://stock-news.laohu8.com/highlight/detail?id=1129937392","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129937392?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 15:05","pubTimestamp":1779865544,"startTime":"0","endTime":"0","summary":"澳大利亚药品管理局（TGA）发布通告，明确特定批次的苄星青霉素钠注射液产品将继续供应，直至现有库存完全耗尽。这一决定旨在确保医疗服务的连续性，为依赖该药品的患者提供明确的供应预期。TGA将持续监控库存与分发情况，以保障公共卫生需求得到满足。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","CSL.AU","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108861620","title":"CSL加拿大宣佈首例加拿大患者於安大略省接受Hemgenix®血友病B基因療法","url":"https://stock-news.laohu8.com/highlight/detail?id=1108861620","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108861620?lang=zh_tw&edition=fundamental","pubTime":"2026-05-20 18:01","pubTimestamp":1779271295,"startTime":"0","endTime":"0","summary":"CSL加拿大公司宣布，首例加拿大患者已在安大略省成功接受了Hemgenix®（Etranacogene Dezaparvovec）基因疗法，用于治疗血友病B。这一里程碑事件标志着该创新疗法在加拿大临床应用的正式开启。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7511","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169753180","title":"泛美衞生組織簽署協議 為拉美及加勒比地區預留大流行流感疫苗供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1169753180","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169753180?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 02:31","pubTimestamp":1778610671,"startTime":"0","endTime":"0","summary":"泛美卫生组织（PAHO）已签署一项关键协议，旨在为拉丁美洲及加勒比地区预先保留大流行性流感疫苗的供应。此举旨在加强该区域应对未来潜在流感大流行的准备能力，确保疫苗的及时获取与分配。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7508","BK7067","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152457110","title":"異動解讀 | 花旗下調評級與目標價，CSL盤中大跌5.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152457110","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152457110?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 08:38","pubTimestamp":1778546311,"startTime":"0","endTime":"0","summary":"CSL LIMITED（CSL.AU）今日盘中大跌5.74%，引发了市场关注。消息面上，花旗集团将CSL的评级从“买入”下调至“中性”，并将其目标价从200澳元大幅下调至110澳元，同时下调了对该公司2026财年的利润预期。此外，投资研究机构晨星也下调了对CSL未来十年的营收和净利润预测。更为直接的是，CSL公司自身在近期下调了年度利润预期，并警告将计提高达50亿澳元的减值准备。晨星分析师指出，鉴于销售势头不足，公司的高营收增长前景难以令人信服，并敦促公司聘请新任首席执行官并提出清晰的发展愿景以重振旗鼓。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634514642","title":"熱門話題-花旗下調目標價，晨星敦促公司聘請新首席執行官，CSL股價下跌6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634514642","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634514642?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 08:34","pubTimestamp":1778546096,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL4T41P021:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791807156.HKD","BK4559","LU2236285917.USD","BK4207","LU2456880835.USD","BK4534","LU1244550221.USD","LU1244550577.SGD","LU2417539215.USD","LU0320765646.SGD","LU0052756011.USD","LU2360032135.SGD","LU0648001328.SGD","CSL.AU","LU0170899867.USD","LU2125154778.USD","LU0477156953.USD","IE00BSNM7G36.USD","LU0203347892.USD","LU0130102774.USD","BK4585","LU1668664300.SGD","BK4504","LU0980610538.SGD","LU2462157665.USD","BK4588","BK7501","BK7067","LU0203345920.USD","LU0128525689.USD","LU1162221912.USD","LU1201861249.SGD","LU1506573853.SGD","BK7511","LU0310800965.SGD","LU0314106906.USD","BK7508","LU1244550494.USD","LU0072461881.USD","LU0162691827.USD","LU0098860793.USD","LU1366192091.USD","LU0106831901.USD","LU2125154935.USD","LU0130517989.USD","LU1267930227.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195739661","title":"異動解讀 | CSL預計美國免疫球蛋白渠道庫存正常化影響收入，股價盤中大跌10.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195739661","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195739661?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 08:04","pubTimestamp":1778457845,"startTime":"0","endTime":"0","summary":"CSL LIMITED今日盘中大跌10.49%，引发了市场关注。消息面上，CSL LIMITED预计，美国市场免疫球蛋白产品的渠道库存恢复正常水平，将对其2026财年的收入造成约3亿美元的影响。这一负面财务预测是导致股价下跌的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168012814","title":"CSL有限公司下調財年展望並計提50億澳元減值，早盤股價重挫10.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168012814","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168012814?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 08:02","pubTimestamp":1778457757,"startTime":"0","endTime":"0","summary":"CSL有限公司在早盘交易中股价大幅下挫10.8%，此前该公司宣布下调2026财年的业绩展望，并确认了高达50亿澳元的资产减值损失。减值主要涉及部分研发项目及生产设施的账面价值调整。管理层同时调整了对2026财年的业绩指引，将原先预期的营收增长区间从“高个位数百分比”下调至“中个位数百分比”，并将核心利润增长预期从“双位数百分比”调整为“高单位数百分比”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","CSL.AU","BK7508","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108549225","title":"CSL預計美國免疫球蛋白渠道庫存正常化將影響2026財年3億美元收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1108549225","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108549225?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 06:16","pubTimestamp":1778451388,"startTime":"0","endTime":"0","summary":"CSL LIMITED预计，美国市场免疫球蛋白产品的渠道库存恢复正常水平，将对其2026财年的收入造成约3亿美元的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7511","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629107268","title":"澳大利亞 CSL 受五角大樓流感政策轉變影響，股價跌至 2017 年新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2629107268","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629107268?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 08:38","pubTimestamp":1776904708,"startTime":"0","endTime":"0","summary":"澳大利亚 CSL 受五角大楼流感政策转变影响，股价跌至 2017 年新低CSL 创 2017 年 8 月底以来最低水平2026 年迄今股价下跌超过 25分析师：五角大楼此举在最糟糕的时候增加了压力Rajasik Mukherjee. CSL Seqirus 在 2025 财年的收入约为 21.7 亿美元，约占公司总收入的 14%。CSL 曾经是澳大利亚最昂贵的股票，去年却暴跌了约 39%，创下了自 2002 年以来的最大年度跌幅。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL4T41601X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7067","BK7511","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626924841","title":"BUZZ-花旗銀行認為季度增長強勁，但可能對瑞思邁的成本產生影響","url":"https://stock-news.laohu8.com/highlight/detail?id=2626924841","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626924841?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 03:30","pubTimestamp":1775676628,"startTime":"0","endTime":"0","summary":"BUZZ-花旗银行认为季度增长强劲，但可能对瑞思迈的成本产生影响4月8日 - ** 花旗预计瑞思迈RMD.AXRMD.N26财年第三季度营收为14.4亿美元，而25财年第三季度为13亿美元。** 花旗将 RMD 第三季度毛利率预期下调 10 个基点，理由是当前地缘政治局势导致成本上升。** 花旗表示：\"我们预测 RMD 的核心每股收益为 2.85 美元，接近 VA 的共识。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4S40R1PB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","RMD","IE00B5TLWC47.USD","BK4567","BK7067","BK4548","BK7511","LU0170899867.USD","LU2008162690.USD","BK4585","BK4588","BK7501","LU2177674079.SGD","BK4504","BK4082","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128146914","title":"美國行政公告確認血漿衍生療法的獨特性，CSL有限公司受益","url":"https://stock-news.laohu8.com/highlight/detail?id=1128146914","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128146914?lang=zh_tw&edition=fundamental","pubTime":"2026-04-07 06:28","pubTimestamp":1775514498,"startTime":"0","endTime":"0","summary":"美国政府在最新行政公告中明确认可了血浆衍生疗法的独特属性，这一决定对专注于该领域的CSL有限公司具有积极意义。血浆衍生疗法因其不可替代的治疗价值与复杂的生产工艺，在全球医疗体系中占据特殊地位。\n此次官方认可不仅凸显了此类疗法对患者生命健康的关键作用，更为CSL有限公司等深耕血浆技术研发的企业提供了政策支持。随着美国对血浆衍生疗法独特性的正式承认，相关企业在供应链保障和市场准入方面有望获得更有利的发展环境。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL.AU","BK7508","BK7511","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620471351","title":"CSL 表示出血性疾病基因療法全球缺貨","url":"https://stock-news.laohu8.com/highlight/detail?id=2620471351","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620471351?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 00:37","pubTimestamp":1773765430,"startTime":"0","endTime":"0","summary":"路透3月17日 - 澳大利亚CSLCSL.AX公司表示，其出血性疾病基因疗法Hemgenix面临暂时性全球缺货，这将推迟该药物在已上市国家的部分患者的治疗。医生们认为，高昂的价格、物流问题和潜在的治疗进展前景阻碍了血友病基因疗法的采用。CSL表示，推迟治疗可能会影响到一些符合条件的患者，这些患者原本计划在已上市的国家接受一次性治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4051K5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","IE00BBT3K403.USD","BK4533","LU0225771236.USD","LU1057294990.SGD","LU1066051498.USD","LU1894683264.USD","BK4550","BK4585","IE00BLSP4239.USD","SG9999002224.SGD","CSL.AU","IE000M9KFDE8.USD","BK4534","SG9999001176.USD","LU1883839398.USD","LU1894683348.USD","IE00BLSP4452.SGD","BK4568","LU0289739699.SGD","IE00B19Z3B42.SGD","LU0985481810.HKD","LU0456855351.SGD","BK7508","LU0170899867.USD","BK4007","LU1066053197.SGD","BK4581","SG9999013999.USD","SG9999011175.SGD","BK7501","IE0002270589.USD","BK4599","LU0058720904.USD","BK4588","IE00B19Z3581.USD","BK4592","LU0225284248.USD","LU0306806265.USD","LU0321505868.SGD","SGXZ57979304.SGD","LU1023059063.AUD","SG9999003800.SGD","LU0122379950.USD","LU0321505439.SGD","BK7511","BK7067","LU0234572021.USD","LU0306807586.USD","SG9999001176.SGD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128210509","title":"CSL有限公司正與監管機構協作制定策略 確保Hemgenix持續穩定供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1128210509","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128210509?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 23:47","pubTimestamp":1773762439,"startTime":"0","endTime":"0","summary":"全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。此次战略合作凸显了CSL对患者用药可及性的长期承诺。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7511","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138284712","title":"CSL Seqirus將攜手長期合作伙伴Sinergium Biotech 供應差異化流感疫苗組合","url":"https://stock-news.laohu8.com/highlight/detail?id=1138284712","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138284712?lang=zh_tw&edition=fundamental","pubTime":"2026-03-10 23:02","pubTimestamp":1773154962,"startTime":"0","endTime":"0","summary":"CSL有限公司旗下业务单元CSL Seqirus宣布，将与其长期合作伙伴Sinergium Biotech合作，共同供应其差异化的流感疫苗产品组合。此次合作旨在进一步拓展相关市场的疫苗可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171042919","title":"世衞組織若宣佈流感大流行 CSL旗下Seqirus將為加拿大提供佐劑化細胞培養疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1171042919","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171042919?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 21:05","pubTimestamp":1772715958,"startTime":"0","endTime":"0","summary":"如果世界卫生组织正式宣布进入流感大流行状态，CSL LIMITED（CSL.AU）旗下疫苗业务部门Seqirus已准备就绪，将向加拿大供应先进的佐剂化细胞培养流感疫苗。\n这种基于细胞培养技术生产的疫苗，相较于传统鸡胚培养方式，具有生产周期更短、应对病毒变异更灵活的优势。结合佐剂技术后，能有效增强免疫反应，在疫苗抗原用量相同的情况下可保护更多人群。\n该合作协议体现了加拿大政府对公共卫生应急能力的前瞻性布局，也展示了CSL集团在生物制药领域的技术储备与全球协作能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7511","CSL.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}